Urinary levels of Hepatocarcinoma-intestine-pancreas/Pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer. - Archive ouverte HAL Access content directly
Journal Articles BMC Urology Year : 2012

Urinary levels of Hepatocarcinoma-intestine-pancreas/Pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer.

(1) , (2) , (1) , (1) , (1) , (3) , (1) , (2)
1
2
3
Yujiro Nitta
  • Function : Author
  • PersonId : 932196
Tetsuya Makino
  • Function : Author
  • PersonId : 932198
Tomoaki Tanaka
  • Function : Author
  • PersonId : 932199
Hidenori Kawashima
  • Function : Author
  • PersonId : 932200
Juan Iovanna
  • Function : Author
  • PersonId : 932201
Tatsuya Nakatani
  • Function : Author
  • PersonId : 932202

Abstract

UNLABELLED: ABSTRACT: BACKGROUND: To assess the possibility of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP) as a biological marker for detecting Bladder cancer (BCa), we examined the expression of HIP/PAP in both BCa specimens and BCa cell lines and measured HIP/PAP levels in urine from patients with BCa. METHODS: HIP/PAP expression in BCa samples was evaluated by western blot analysis, and urinary levels of HIP/PAP in patients with BCa were measured by enzyme-linked immunosorbent assay. Urine samples were collected from 10 healthy volunteers and 109 with benign urological disorders as controls, and from 101 patients who were diagnosed with BCa. RESULTS: HIP/PAP was highly expressed in BCa samples as compared with control bladder. Urinary HIP/PAP concentrations were significantly higher in BCa patients than in controls (median value; 3.184 pg/mL vs. 55.200 pg/mL, P <0.0001, by Mann-Whitney U test). Urinary HIP/PAP levels in BCa patients correlated positively with pathological T stages and progression-risk groups among non-muscle invasive BCa (P = 0.0008, by Kruskal-Wallis test). Regarding the recurrence-risk classifications of non-muscle invasive BCa, the urinary levels of HIP/PAP were significantly higher in the intermediate than in the low risk group (P = 0.0002, by Mann-Whitney U test). Based on a cut-off of 8.5 pg/mL, the ability of urinary HIP/PAP levels to detect BCa had a sensitivity of 80.2%, specificity of 78.2%, positive predictive value (PPV) of 75.7%, and negative predictive value (NPV) of 82.3%. CONCLUSIONS: HIP/PAP was abundantly expressed in BCa, and the urinary levels of HIP/PAP could be a novel and potent biomarker for detection of BCa, and also for predicting the risks of recurrence- and progression-risk of non-muscle invasive BCa. A large scale study will be needed to establish the usefulness of this biomarker.
Fichier principal
Vignette du fichier
1471-2490-12-24.pdf (463.59 Ko) Télécharger le fichier
Vignette du fichier
1471-2490-12-24.xml (52.88 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other
Loading...

Dates and versions

inserm-00747789 , version 1 (01-11-2012)

Identifiers

Cite

Yujiro Nitta, Hiroyuki Konishi, Tetsuya Makino, Tomoaki Tanaka, Hidenori Kawashima, et al.. Urinary levels of Hepatocarcinoma-intestine-pancreas/Pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer.. BMC Urology, 2012, 12 (1), pp.24. ⟨10.1186/1471-2490-12-24⟩. ⟨inserm-00747789⟩

Collections

INSERM UNIV-AMU
114 View
225 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More